Emergent BioSolutions Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EBS research report →
Companywww.emergentbiosolutions.com
Emergent BioSolutions Inc. , a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.
- CEO
- Joseph C. Papa Jr.
- IPO
- 2006
- Employees
- 900
- HQ
- Gaithersburg, MD, US
Price Chart
Valuation
- Market Cap
- $420.25M
- P/E
- -49.15
- P/S
- 0.62
- P/B
- 0.81
- EV/EBITDA
- 5.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 44.44%
- Op Margin
- 10.52%
- Net Margin
- -1.27%
- ROE
- -1.59%
- ROIC
- -14.93%
Growth & Income
- Revenue
- $742.90M · -28.81%
- Net Income
- $52.60M · 127.60%
- EPS
- $0.98 · 127.22%
- Op Income
- $110.20M
- FCF YoY
- 337.99%
Performance & Tape
- 52W High
- $14.06
- 52W Low
- $5.62
- 50D MA
- $8.31
- 200D MA
- $9.71
- Beta
- 2.33
- Avg Volume
- 891.02K
Get TickerSpark's AI analysis on EBS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 30, 26 | Dayal Sujata Tyagi | other | 25,344 |
| May 1, 26 | Dayal Sujata Tyagi | sell | 12,781 |
| May 1, 26 | Dayal Sujata Tyagi | sell | 980 |
| Apr 30, 26 | Dayal Sujata Tyagi | other | 11,296 |
| Apr 30, 26 | DeGolyer Donald W | other | 25,344 |
| May 1, 26 | DeGolyer Donald W | sell | 14,527 |
| May 1, 26 | DeGolyer Donald W | sell | 954 |
| Apr 30, 26 | DeGolyer Donald W | other | 11,296 |
| Apr 30, 26 | Katkin Keith | other | 25,344 |
| Apr 30, 26 | Katkin Keith | sell | 15,481 |
Our EBS Coverage
We haven't published any research on EBS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EBS Report →